Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND HER1, YOR227W AND Treatment
26 results:

  • 1. Triple Targeting of HER Receptors Overcomes Heregulin-mediated Resistance to EGFR Blockade in colorectal cancer.
    Rau A; Janssen N; Kühl L; Sell T; Kalmykova S; Mürdter TE; Dahlke MH; Sers C; Morkel M; Schwab M; Kontermann RE; Olayioye MA
    Mol Cancer Ther; 2022 May; 21(5):799-809. PubMed ID: 35247930
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies.
    Berlin J; Tolcher AW; Ding C; Whisenant JG; Horak ID; Wood DL; Nadler PI; Hansen UH; Lantto J; Skartved NJØ; Pedersen MW; Patnaik A
    Invest New Drugs; 2022 Jun; 40(3):586-595. PubMed ID: 35113285
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Improving the anticancer effect of afatinib and microRNA by using lipid polymeric nanoparticles conjugated with dual pH-responsive and targeting peptides.
    Hong ST; Lin H; Wang CS; Chang CH; Lin AM; Yang JC; Lo YL
    J Nanobiotechnology; 2019 Aug; 17(1):89. PubMed ID: 31426807
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Lapatinib.
    Voigtlaender M; Schneider-Merck T; Trepel M
    Recent Results Cancer Res; 2018; 211():19-44. PubMed ID: 30069757
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Exploration of a F(ab')
    Milenic DE; Kim YS; Baidoo KE; Wong KJ; Barkley R; Delgado J; Brechbiel MW
    Cancer Biother Radiopharm; 2018 Jun; 33(5):182-193. PubMed ID: 29916748
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced colorectal cancer.
    Seligmann JF; Hatch AJ; Richman SD; Elliott F; Jacobs B; Brown S; Hurwitz H; Barrett JH; Quirke P; Nixon AB; Seymour MT
    JAMA Oncol; 2018 Apr; 4(4):564-568. PubMed ID: 29075780
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Neratinib: First Global Approval.
    Deeks ED
    Drugs; 2017 Oct; 77(15):1695-1704. PubMed ID: 28884417
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. The prospect of patritumab for treating non-small cell lung cancer.
    Horinouchi H
    Expert Opin Biol Ther; 2016 Dec; 16(12):1549-1555. PubMed ID: 27744717
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
    Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
    Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Epidermal growth factor receptor inhibitors: coming of age.
    Mahipal A; Kothari N; Gupta S
    Cancer Control; 2014 Jan; 21(1):74-9. PubMed ID: 24357745
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Peptide vaccines and peptidomimetics of EGFR (HER-1) ligand binding domain inhibit cancer cell growth in vitro and in vivo.
    Foy KC; Wygle RM; Miller MJ; Overholser JP; Bekaii-Saab T; Kaumaya PT
    J Immunol; 2013 Jul; 191(1):217-27. PubMed ID: 23698748
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Zirconium-89 labeled panitumumab: a potential immuno-PET probe for her1-expressing carcinomas.
    Bhattacharyya S; Kurdziel K; Wei L; Riffle L; Kaur G; Hill GC; Jacobs PM; Tatum JL; Doroshow JH; Kalen JD
    Nucl Med Biol; 2013 May; 40(4):451-7. PubMed ID: 23454247
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. 100% human monoclonal antibodies in oncology: hype or breakthrough?
    Benay S; Fanciullino R; Mercier C; Iliadis A; Ciccolini J; Lacarelle B
    Curr Top Med Chem; 2012; 12(15):1643-8. PubMed ID: 22978333
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Monoclonal antibody therapy of pancreatic cancer with cetuximab: potential for immune modulation.
    Luedke E; Jaime-Ramirez AC; Bhave N; Carson WE
    J Immunother; 2012 Jun; 35(5):367-73. PubMed ID: 22576341
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. From chemotherapy to targeted therapy in adjuvant treatment for stage III colon cancer.
    de Gramont A; de Gramont A; Chibaudel B; Bachet JB; Larsen AK; Tournigand C; Louvet C; André T;
    Semin Oncol; 2011 Aug; 38(4):521-32. PubMed ID: 21810511
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Preparation, biological evaluation, and pharmacokinetics of the human anti-her1 monoclonal antibody panitumumab labeled with 86Y for quantitative PET of carcinoma.
    Nayak TK; Garmestani K; Baidoo KE; Milenic DE; Brechbiel MW
    J Nucl Med; 2010 Jun; 51(6):942-50. PubMed ID: 20484421
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. PET imaging of her1-expressing xenografts in mice with 86Y-CHX-A''-DTPA-cetuximab.
    Nayak TK; Regino CA; Wong KJ; Milenic DE; Garmestani K; Baidoo KE; Szajek LP; Brechbiel MW
    Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1368-76. PubMed ID: 20155263
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Mechanisms of resistance to HER family targeting antibodies.
    Kruser TJ; Wheeler DL
    Exp Cell Res; 2010 Apr; 316(7):1083-100. PubMed ID: 20064507
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Antitumor activity of the HER2 dimerization inhibitor pertuzumab on human colon cancer cells in vitro and in vivo.
    Pohl M; Stricker I; Schoeneck A; Schulmann K; Klein-Scory S; Schwarte-Waldhoff I; Hasmann M; Tannapfel A; Schmiegel W; Reinacher-Schick A
    J Cancer Res Clin Oncol; 2009 Oct; 135(10):1377-86. PubMed ID: 19340455
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Epidermal growth factor receptor inhibitor-related skin toxicity: mechanisms, treatment, and its potential role as a predictive marker.
    Bianchini D; Jayanth A; Chua YJ; Cunningham D
    Clin Colorectal Cancer; 2008 Jan; 7(1):33-43. PubMed ID: 18279575
    [TBL] [Abstract] [Full Text] [Related]  


    of 2.